Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
National Institutes of Health
Classification and identifiers
- Solicitation number
- FOR-RFA-AG-26-019
- Assistance listing (CFDA)
- 93.866
Amount
Amount not published by the funder
Who can apply
About this opportunity
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-relat...
Related opportunities
- Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive DeclineNational Institutes of Health
- Infectious Diseases Clinical Trials Network (IDCTN)National Institutes of Health
- Single Source: Cardiothoracic Surgical Trials Network (CTSN) Data Coordinating Center (U01 Clinical Trial Required)National Institutes of HealthCloses tomorrowUp to $8.0M
- DoW Alzheimer’s Transforming Care AwardDefense Health Agency Contracting Activity - DHACACloses in 80 days
- Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)National Institutes of Health
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)National Institutes of HealthCloses in 84 days